APLS

Apellis Pharmaceuticals Inc
63.05
0.03 (0.05%)

Apellis Pharmaceuticals Inc. (APLS) Fundamentals

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.
SHARE INFORMATION
Market CapUS$ 7,013,539,851
Shares Outstanding111,290,699
Float82,475,002
Percent Float74.11%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per ShareUS$ 0.00
Latest Fiscal RevenueUS$ 75,422,000
Latest Fiscal EPSUS$ -6.13
Latest Fiscal Date2022-12-31
DIVIDENDS
Dividend (3 Years)US$ 0.00
Dividend (5 Years)US$ 0.00
Ex Dividend Date-
Dividend RateUS$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions592
Institutional Holdings Date2023-02-28
Institutional Bought Previous 3 Months16,282,615
Institutional Holdings Percent155.9%
Institutional Sold Previous 3 Months10,308,786
Insider Holdings Date2023-02-28
Insider Bought Previous 3 Months1,308,525
Insider Holdings Percent4.0
Insider Sold Previous 3 Months429,196
Insider Shares Owned4,416,886
TRADING INFO
52 Week HighUS$ 70.76
52 Week LowUS$ 33.32
52 Week High ChangeUS$ 34.54
21 Day Moving AverageUS$ 63.3133
21 Day Extended Moving AverageUS$ 62.3645
50 Day Moving AverageUS$ 56.7144
50 Day Extended Moving AverageUS$ 58.714
200 Day Moving AverageUS$ 54.8894
200 Day Extended Moving AverageUS$ 54.3411
10 Day Average Volume1,847,751
20 Day Average Volume2,585,164
30 Day Average Volume2,077,001
50 Day Average Volume1,749,639
Alpha0.027980
Beta1.1856
Standard Deviation0.176257
R20.131218
7 Day Price ChangeUS$ 0.80
7 Day Percent Change1.29%
21 Day Price ChangeUS$ -3.67
21 Day Percent Change-5.5%
30 Day Price ChangeUS$ 7.53
30 Day Percent Change13.57%
Month to Date Price ChangeUS$ -2.46
Month to Date Percent Change-3.76%
Quarter to Date Price ChangeUS$ 11.31
Quarter to Date Percent Change21.87%
180 Day Price ChangeUS$ 0.46
180 Day Percent Change0.74%
200 Day Price ChangeUS$ 4.92
200 Day Percent Change8.47%
Year to Date Price ChangeUS$ 11.31
Year to Date Percent Change21.87%

Apellis Pharmaceuticals Inc. (APLS) Key Ratios

PROFITABILITY
EBIT Margin-534.0%
EBITDA Margin-532.8%
Pre-Tax Profit Margin0.0%
Profit Margin Count-89.24%
Gross Margin92.5%
Profit Margin TOT-89.24%
INCOME STATEMENTS
RevenueUS$ 75,422,000
Revenue Per ShareUS$ 0.6777
Revenue (3 Years)US$ 0.00
Revenue (5 Years)US$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book41.30
Total Debt To Equity0.70
Int Coverage-19.00
Current Ratio4.30
Leverage Ratio3.00
Quick Ratio3.30
Long Term Debt To Capital0.39
VALUATION MEASURES
PE Ratio-10.90
Enterprise ValueUS$ 6,574,451,850
Price to Sales92.9906
Price to Free Cash-13.60
PE High Last 5 Years-7.40
Price To Book41.30
Price To Cash Flow0.00
PE Low Last 5 Years-6.00
Price to Tangible Book41.30
MANAGEMENT EFFECTIVENESS
Receivables Turnover8.40
Invoice Turnover0.10
Assets Turnover0.10
Return Assets-81.93
Return on Equity-365.09
Return on Capital-215.54

Apellis Pharmaceuticals Inc. (APLS) Profile

PROFILE INFO
Issue TypeCS
SEC Type-
AuditorDeloitte & Touche LLP
CEOCedric Francois
Emplyoees767
Last AuditUE
CIK0001492422
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address100 Fifth Avenue
Waltham, MA 2451
Websitehttps://www.apellis.com
Facsimile-
Telephone+1 617 977-5700
Emailinvestors@apellis.com
Your Recent History
NASDAQ
APLS
Apellis Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now
NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:au D:20230321 02:26:56